$ARVN

Arvinas Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Medicinal and Botanical Manufacturing

PRICE

$43.19 -

Extented Hours

VOLUME

464,311

DAY RANGE

40.65 - 43.3

52 WEEK

37.41 - 108.47

Join Discuss about ARVN with like-minded investors

profile
@dros #droscrew
recently

+Initiations 1/19: $ADSE $ARVN $ARWR $CMPX $DCGO $FATH $FFIV $GENI $GRAB $INVO $JNPR $KPRX $LEE $NET $NTNX $SOFI $USFD $VMW . -Initiations 1/19: $CLFD $DSGN $OPEN

52 Replies 14 👍 9 🔥

profile
@dros #droscrew
recently

Upgrades 11/4: $ANDE $APA $ARVN $BXC $CADE $CPRI $CLR $CUTR $DNOW $ETR $KNBE $LYFT $MAC $MAXR $MRCC $NCMI $QCOM $QLYS $RS $SEE $SHBI $SYNH

113 Replies 11 👍 15 🔥

profile
@viking #StockTraders.NET
recently

im watching $ARVN and $ABUS

88 Replies 11 👍 13 🔥

profile
@viking #StockTraders.NET
recently

vol dropping on $ARVN

74 Replies 15 👍 11 🔥

profile
@dros #droscrew
recently

$ARVN monster still

51 Replies 9 👍 12 🔥

profile
@TraderXx #StockTraders.NET
recently

not trading today, just looked at $ARVN, whats up with this one?

87 Replies 11 👍 13 🔥

profile
@Navneet #droscrew
recently

you didnt even tell me to get $arvn

99 Replies 13 👍 6 🔥

profile
@CarlosH-carvan #ivtrades
recently

$ARVN raised to $120

135 Replies 9 👍 6 🔥

profile
@RedSunCap #droscrew
recently

out ARVN at 35 in a 2.25

140 Replies 13 👍 14 🔥

profile
@ashy2classy #droscrew
recently

dros you get arvn?

117 Replies 15 👍 9 🔥

profile
@Navneet #droscrew
recently

$arvn wtf was that 71$ ?

54 Replies 6 👍 15 🔥

profile
@dros #droscrew
recently

damn $ARVN

65 Replies 15 👍 6 🔥

profile
@dros #droscrew
recently

2714 $ARVN 18DEC20 $35 Cs trade 2.25

63 Replies 10 👍 6 🔥

profile
@dros #droscrew
recently

2714 $ARVN 18DEC20 $35 Cs trade 2.25

136 Replies 7 👍 8 🔥

Key Metrics

Market Cap

2.30 B

Beta

1.32

Avg. Volume

582.36 K

Shares Outstanding

53.17 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-04

Next Dividend Date

Company Information

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and "undruggable" targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.

Website:

HQ: ,

Related News